The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).

被引：0
|
作者：
Kosugi, Chihiro
Kamiyama, Hirohiko
Yoshida, Yoichiro
Yoshida, Hiroshi
Ishibashi, Keiichiro
Ihara, Keisuke
Takahashi, Makoto
Kuramochi, Hidekazu
Sonoda, Hiromichi
Yoshimatsu, Kazuhiko
Fukazawa, Atsuko
Matsuda, Akihisa
Yamaguchi, Satoru
Ishida, Hideyuki
Hasegawa, Suguru
Yamada, Takeshi
Narushima, Kazuo
Shuto, Kiyohiko
Sakamoto, Kazuhiro
Koda, Keiji
机构：
[1] Teikyo Univ, Chiba Med Ctr, Ichihara, Chiba, Japan
[2] Juntendo Univ, Sch Med, Dept Coloproctol Surg, Bunkyo Ku, Tokyo, Japan
[3] Fukuoka Univ, Fukuoka, Fukuoka, Japan
[4] Nippon Med Univ, Dept Gastroenterol Surg, Tokyo, Japan
[5] Saitama Med Univ, Saitama, Japan
[6] Dokkyo Univ, Dept Surg Oncol, Sch Med, Mibu, Tochigi, Japan
[7] 3-1-3 Hongo,Bunkyo Ku, Tokyo, Japan
[8] Tokyo Womens Med Univ, Yachiyo Med Ctr, Yachiyoshi Chiba, Japan
[9] Shiga Univ Med Sci, Dept Surg, Otsu, Shiga, Japan
[10] Saiseikai Kurihashi Hosp, Dept Surg, Kuki, Saitama, Japan
[11] Iwata City Hosp, Dept Surg, Iwata, Shizuoka, Japan
[12] Chiba Hokusoh Hosp, Nippon Med Sch, Dept Surg, Chiba, Japan
[13] Fukuoka Univ, Sch Med, Dept Gastroenterol Surg, Fukuoka, Fukuoka, Japan
[14] Nippon Med Sch, Dept Digest Surg, Tokyo, Japan
[15] Teikyo Univ, Chiba Med Ctr, Ichihara, Chiba, Japan
[16] Juntendo Univ, Sch Med, Dept Coloproctol Surg, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.614
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
614
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer
    Ishizaki, Tetsuo
    Mazaki, Junichi
    Enomoto, Masanobu
    Shigoka, Masatoshi
    Kasahara, Kenta
    Matsudo, Takaaki
    Kawakita, Hideaki
    Nagakawa, Yuichi
    Katsumata, Kenji
    Tsuchida, Akihiko
    ANTICANCER RESEARCH, 2021, 41 (04) : 2157 - 2163
  • [32] Retrospective study of TAS-102 plus bevacizumab for patients with metastatic colorectal cancer in salvage therapy
    Hisamatsu, A.
    Ikusue, T.
    Toshima, H.
    Kobayashi, K.
    Shimada, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).
    Cecchini, Michael
    Kortmansky, Jeremy S.
    Lacy, Jill
    Fischbach, Neal A.
    Thumar, Jaykumar Ranchodbhai
    Sabbath, Kert D.
    Gomez, Christina M.
    Sporn, Jonathan
    Stein, Stacey
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [34] TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice
    Shin, Ji Eun
    Lim, Sung Hee
    Lee, Jeeyun
    Lim, Ho Yeong
    Park, Young Suk
    Kim, Seung Tae
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [35] TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice
    Shin, J. E.
    Cho, S.
    Lee, J.
    Kim, S. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1443 - S1443
  • [36] Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
    Mayer, Robert J.
    Van Cutsem, Eric
    Falcone, Alfredo
    Yoshino, Takayuki
    Garcia-Carbonero, Rocio
    Mizunuma, Nobuyuki
    Yamazaki, Kentaro
    Shimada, Yasuhiro
    Tabernero, Josep
    Komatsu, Yoshito
    Sobrero, Alberto
    Boucher, Eveline
    Peeters, Marc
    Tran, Ben
    Lenz, Heinz-Josef
    Zaniboni, Alberto
    Hochster, Howard
    Cleary, James M.
    Prenen, Hans
    Benedetti, Fabio
    Mizuguchi, Hirokazu
    Makris, Lukas
    Ito, Masanobu
    Ohtsu, Atsushi
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20): : 1909 - 1919
  • [37] Phase II study of TAS-OX (TAS-102 and oxaliplatin) plus bevacizumab for late-line colorectal cancer.
    Hochster, Howard S.
    Liu, Hao
    Berim, Lyudmyla Derby
    Spencer, Kristen Renee
    Gulhati, Pat
    DiRubbo, Manda
    Cohen, Seth D.
    Lee, Patrick
    Leitner, Stuart P.
    Radovich, Delia
    Misdary, Christian
    Perez, Christian
    Datta, Sutirtha
    Gonzalez, Andrea
    Saunders, Tracie
    Boland, Patrick M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 144 - 144
  • [38] Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer
    Arita, Shuji
    Shirakawa, Tsuyoshi
    Matsushita, Yuzo
    Shimokawa, Hozumi Kumagai
    Hirano, Gen
    Makiyama, Akitaka
    Shibata, Yoshihiro
    Tamura, Shingo
    Esaki, Taito
    Mitsugi, Kenji
    Ariyama, Hiroshi
    Kusaba, Hitoshi
    Akashi, Koichi
    Baba, Eishi
    ANTICANCER RESEARCH, 2016, 36 (04) : 1959 - 1966
  • [39] Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer
    Zhang, Jing
    Yang, Wenwei
    Liu, Junbao
    Wang, Nan
    Ren, Zhaoying
    Yang, Tingting
    Xie, Gongli
    Wu, Guifu
    Sun, Yongkun
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (04) : 454 - 461
  • [40] Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
    Conti, Matteo
    Bolzacchini, Elena
    Luchena, Giovanna
    Bertu', Lorenza
    Tagliabue, Paola
    Aglione, Stefania
    Ardizzoia, Antonio
    Arnoffi, Jessica
    Guida, Francesco Maria
    Bertolini, Alessandro
    Pastorini, Alessandro
    Duro, Maria
    Bettega, Donato
    Roda', Giovambattista
    Artale, Salvatore
    Squizzato, Alessandro
    Giordano, Monica
    CANCERS, 2023, 15 (13)
12345